MARC21

000	00000nam 2200000zi 4500
001	9.935235
003	CaOODSP
005	20240620110958
006	m o d f
007	cr \|\|\|\|\|\|\|\|\|\|\|
008	240311t20242024onc ob f000 0 eng d
020	\|a9780660707341
040	\|aCaOODSP\|beng\|erda\|cCaOODSP
043	\|an-cn---
086	1 \|aH14-443/2024E-PDF
245	00\|aMpox immunization coverage survey among 2SLGBTQI+ and men who have sex with men, 2024 : \|bmethodological report / \|cprepared for the Public Health Agency of Canada.
264	1\|aOttawa, Ontario : \|bPublic Health Agency of Canada = Agence de la santé publique du Canada, \|c2024.
264	4\|c©2024
300	\|a1 online resource (33 pages) + \|esummary (4 pages)
336	\|atext\|btxt\|2rdacontent
337	\|acomputer\|bc\|2rdamedia
338	\|aonline resource\|bcr\|2rdacarrier
500	\|aIssued also in French under title: Enquête sur la couverture vaccinale contre la variole simienne chez les 2SLGBTQI+ et les hommes ayant des rapports sexuels avec des hommes, 2024 : rapport méthodologique.
500	\|a"Supplier name: Advanis Inc."
500	\|a"Contract number: 6D142-23-4971."
500	\|a"Registration number: POR 093-23."
504	\|aIncludes bibliographical references.
520	\|a"The purpose of this survey was to provide an update in 2023/2024 to the information on mpox vaccine coverage for the 2SLGBTQI+ as well as MSM adult populations, and continue to help understand the knowledge, attitudes, and beliefs concerning mpox vaccines (e.g., vaccine effectiveness, vaccine safety, vaccine relevance). This includes exploring reasons for vaccine hesitancy and vaccine refusal and the impact this has on vaccine. Its purpose was also to identify risk factors for transmission of mpox as well as these populations’ willingness to limit high-risk activities amid the current mpox outbreak"--Executive summary, page 4.
650	0\|aHuman monkeypox\|xVaccination\|zCanada\|xPublic opinion.
650	0\|aPublic opinion\|zCanada.
650	0\|aSexual minorities\|zCanada\|xAttitudes.
710	2 \|aPublic Health Agency of Canada, \|eissuing body.
710	2 \|aAdvanis (Firm), \|econsultant.
775	08\|tEnquête sur la couverture vaccinale contre la variole simienne chez les 2SLGBTQI+ et les hommes ayant des rapports sexuels avec des hommes, 2024 : \|w(CaOODSP)9.935236
795	\|tMpox immunization coverage survey among 2SLGBTQI+ and men who have sex with men : \|w(CaOODSP)9.924899
856	40\|qPDF\|s785 KB\|uhttps://publications.gc.ca/collections/collection_2024/aspc-phac/H14-443-2024-eng.pdf\|zMethodological Report
856	40\|qPDF\|sKB\|uhttps://publications.gc.ca/collections/collection_2024/aspc-phac/H14-443-2024-1-eng.pdf\|z(Summary)
856	4 \|qHTML\|sN/A\|uhttps://epe.bac-lac.gc.ca/100/200/301/pwgsc-tpsgc/por-ef/public_health_agency_canada/2024/093-23-e/POR093-23-report.html\|zMethodological Report
856	4 \|qHTML\|sN/A\|uhttps://epe.bac-lac.gc.ca/100/200/301/pwgsc-tpsgc/por-ef/public_health_agency_canada/2024/093-23-e/summary/POR093-23-summary.html\|zExecutive Summary